

June 17, 2022

To whom it may concern:

Company Name	TOHO HOLDINGS CO., LTD.
Corporate Representative	Atsushi Udoh, President and Representative Director (Prime Market of Tokyo Stock Exchange Securities Code: 8129)
Contact:	Makoto Kawamura, Director and General Manager, Corporate Planning and Investor Relations Department (TEL: 81-3-6838-2803)

Notice Regarding Launch of  
2 Ingredients / 3 Products of Generic Drugs for KYOSOMIRAI PHARMA

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Nobuaki Hosaka), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has launched 2 ingredients / 3 products of generic drugs today on June 17, 2022 as below.

New products list

Classes	Product Name	Original Brand Name
EPA and DHA preparation	Omega-3-Acid ethyl esters Granular Capsules 2g “MJT”	LOTRIGA®2g
Levocarnitine preparation	LEVOCARNITINE FF TABLETS 100mg/ 250mg “TOWA”	L-Cartin®FF tablets 100mg/250mg